Header
From the inception of a therapeutic through early clinical development, our disease area teams collaborate across scientific disciplines and organizations in support of our mission to improve and extend peoples’ lives.

 

Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow and is responsible for the largest number of leukemia deaths annually. Learn more about this aggressive disease.

Learn More

ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Learn about ALK+ advanced non-small cell lung cancer (NSCLC) and Novartis Oncology’s commitment to research & development for patients living with this genetically driven disease.

Learn More

 

Chagas disease

Together with partners, we are committed to reimagining the fight against Chagas disease and advocating for an integrated, end-to-end care approach.

Learn More

Chronic Myeloid Leukemia (CML)

Chronic myeloid leukemia, or CML, is a relatively slow-growing cancer of the blood and bone marrow, which affects one to two people in every 100,000 people every year.

Learn More

 

Coronavirus disease (COVID-19)

Novartis is responding to the coronavirus disease (COVID-19) with safety of associates and patients globally as our primary concern. We are also contributing to research efforts, supporting communities and ensuring stable supply and price of essential medicines.

Learn More

Heart Failure

Heart failure is a debilitating and potentially life-threatening condition where the heart cannot pump enough blood around the body, leaving patients fatigued, short of breath, and at risk of sudden cardiac death.

Learn More

 

Leprosy

For more than 30 years, Novartis and the Novartis Foundation have been working with partners around the world to eliminate leprosy – and we are committed to going the last mile.

Learn More

Malaria

We have been committed to the fight against malaria for the past two decades. Today we are working on the development of the next generation of antimalarials.

Learn More

 

 

Melanoma

Melanoma is the most serious type of skin cancer, and many times, it is caused by damage to the DNA in skin cells.

Learn More

Multiple Myeloma

Learn about multiple myeloma and Novartis Oncology’s commitment to research & development for patients living with this rare cancer.

Learn More

 

 

Sickle cell disease (SCD)

Novartis is pursuing a comprehensive approach to tackling SCD. We are developing innovative new medicines to treat it and are working to expand access to diagnosis, treatment and care.

Learn More

Spinal Muscular Atrophy (SMA)

SMA is a rare and devastating genetic disease caused by a lack of a functional survival motor neuron 1 (SMN1) gene, resulting in the rapid and irreversible loss of motor neurons.

Learn More